Pharmacological, behavioral, and receptor binding studies have suggested the existence of at least three types of opioid receptors in the mammalian brain-& k, and K (for references, see Simon and Gioannini, 1993) . These receptors have specific pharmacological profiles (Lutz and Pfister, 1992) and have been associated with various physiological functions (Herz, 1993) . The biosyn-thetic precursors of each of the opioid peptides contain several possible biologically active products (e.g., met-and leu-enkephalin; dynorphin Al-S, dynorphin Al-13, dynorphin Al-17; p-endorphin) that exert physiological actions by interacting with opioid receptors (Simon, 1991) . Enkephalins from the proenkephalin gene are thought to be ligands for &opioid receptors, whereas dynorphins of varied lengths, derived from the prodynorphin gene, have been suggested to be ligands for K-opioid receptors (Corbett et al., 1993) . The identity of the endogenous ligand for F-opioid receptors is uncertain; however, candidates include P-endorphin (derived from the proopiomelanocortin gene) and the enkephalins. Binding sites that are thought to represent the k-opioid receptor are widely distributed throughout the brain and spinal cord (Mansour et al., 1987; Tempel and Zukin, 1987; Mansour and Watson, 1993) . High densities of binding are found in regions such as the caudate-putamen (in striatal patches and in the subcallosal streak), thalamus, interpeduncular nuclei, locus coeruleus, nucleus of the solitary tract, and the dorsal horn of the spinal cord. This distribution of binding sites is consistent with some of the presumed actions of y-opioid receptors, including those of sensorimotor integration and pain modulation. Following the cloning of a &opioid receptor (Evans et al., 1992; Kieffer et al., 1992) , a k-opioid receptor was cloned from rat (MORl; Chen et al., 1993; Fukuda et al., 1993; Thompson et al., 1993) . The anatomical distribution of mRNA coding for this receptor correlates well with the distribution of p.-opioid binding sites (Thompson et al., 1993; Delfs et al., 1994; Mansour et al., 1994) . This correlation suggests that p-opioid receptors are not transported far from their sites of synthesis, making it likely that they are used either as presynaptic receptors in local circuit neurons, as postsynaptic receptors in the dendrites and perikarya of neurons that express the MORl transcript, or both.
In recent studies, we found that the cloned &opioid receptor (DORl) is targeted almost exclusively to axons (Dado et al., 1993; Arvidsson et al., 1995) , where it most likely functions presynaptically (Glaum et al., 1994) . Given the high degree of structural similarity between MORI and DORl (55% homology at the amino acid level), we found it of interest to determine if neurons in various brain regions target MORl in a manner similar to or different from DOR 1. We present evidence that MOR 1 is predominantly targeted to the somatodendritic domain, where it most likely functions postsynaptically, although certain groups of neurons direct it to their axons.
Materials and Methods
Generution of anti-p@& antisera. Antisera against MORI were produced in six New Zealand White rabbits against a 15-residue peptide (NHQLENLEAETAPLP) corresponding to amino acids 384-398 predicted from the cloned rat MORl (Chen et al., 1993; Fukuda et al., 1993; Thompson et al., 1993) . The peptide was synthesized using an Applied Biosystems 432A solid-phase peptide synthesizer. The peptide (10 mglml) was conjugated to bovine thyroglobulin (Sigma, St. Louis, MO; 40 mg/ml) using 7% glutaraldehyde (Sigma; 30 yl/ml). For initial immunizations 1 mg of the peptide-thyroglobulin conjugate was emulsified with an equal volume of Freund's complete adjuvant (Difco, Detroit, MI) and injected in each of six rabbits (551-556). Subsequent immunizations consisted of 0.5 mg of the conjugate emulsified with an equal volume of Freund's incomplete adjuvant administered at 2 week intervals. Serum was obtained 1 week after immunizations, beginning with the third week. Sera from rabbits 55 1 and 552 were used throughout the study unless otherwise noted.
Construc6on
of epitope-tagged opioid receptor and expression of these receutors in COS-7 and NeuroZa cells. MORI cDNA was ligated into a pRC/CMV vector (Invitrogen, San Diego, CA) at HindIII"sites as described (Chen et al., 1993) . The human influenza virus hemagglutinin epitope-tagged MORI (hereafter referred to as MORTAG) was constructed by using polymerase chain reaction to insert 39 nucleotides (TACCCATACGATGTGCCCGACTATGCTCTGGTGCCGCGG) immediately 3' to the initiation ATG. The oligodeoxynucleotide was synthesized by flanking the nucleotide sequence coding for this epitope on both sides with a 15 nucleotide sequence from MORl (upstream GCCTTCAGCACCATG; downstream GACAGCAGCACCGGC). Analogous oligodeoxynucleotide sequences for constructing epitopetagged DORl and KORl were used. As for the downstream primer in the polymerase chain reaction, the SP6 promoter sequence of the pRC/ CMV plasmid was used for generation of the MORTAG fragment. The sequence of DORl between nucleotides 308 and 332, which encompassed the ScaI site, was used as downstream primer for DORTAG. The sequence of KORl between nucleotides 374 and 393, which encompassed the unique PflMI site, was used as downstream primer for KOR-TAG. The resulting fragments were subcloned into PCRII plasmid (Invitrogen) . For MORTAG, the complete epitope-tagged receptor was excised from PCRII plasmid and subcloned into the pCDNA3 plasmid (Invitrogen) at Hind111 and XbaI sites. For DORTAG, the fragment was excised from PCRII with Hind111 and ScaI and ligated with pCDNA3 digested with Hind111 and XbaI, and a 1.4 kb DORl fragment isolated by digesting DORl with ScaI and XbaI. Similarly, KORTAG was generated by excising from PCRII with Hind111 and PflMI, subcloned into pCDNA3 plasmid linearized with Hind111 and XbaI together with a 1.35 kb fragment of KORl isolated after PflMI and XbaI digestion. Subsequent plasmids were then isolated with alkaline lysis of bacteria and purified using anion-exchange resins (Qiagen, Chatsworth, CA).
The purified plasmids were then introduced into COS-7 cells using electroporation and into Neuro2a cells by calcium phosphate precipitation method as described by Chen and Okayama (1988) . For electroporation, 0.5 ml of COS-7 cells suspended in PBS at concentration of 10' cells/ml was premixed with 10 pg of plasmid DNA. For the stable expression of receptor or epitope-tagged receptor in Neuro2a cells, 30 pg of plasmid DNA solution was added to cells previously seeded in 100 mm plates of lo6 cells/l0 ml of medium. The Neuro2a cells incorporating the plasmids were selected by addition of geneticin (G418, GIBCO, Grand Island, NY) 24 hr later. Colonies formed lo-14 d after the addition of G418 were then picked. The stable expression of the opioid receptor by Neuro2a cells was assessed by 'H-diprenorphine binding on intact cells in the presence or absence of 10 FM naloxone for k-and &opioid receptor and 10 PM U50,488 for K-opioid receptor (Bergsbaken et al., 1993 extracts. Cross-linking of 1251-B-endorphin to the p-opioid receptor expressed in MORl-Neuro2a cell membranes was carried out using a modified method of Ko et al. (1992) .
For immunoaffinity purification of either wild-type or epitope-tagged MORl, 2-5 mg of cell membranes was solubilized in 2 ml of solubilizing buffer (25 mM HEPES, pH 7.6; 0.1 PM PMSF; 10 kg/ml leupeptin; 100 kg/ml bacitracin; 1 mM EDTA; 1% Triton X-100) by incubating on ice for 15 min. Afterward, particulates were removed by centrifugation and the supernatant was applied onto a wheat germ lectin column eauilibrated with the runninn buffer (25 mM HEPES. DH 7.6: 100 mM NaCl; 0.1% Triton X-100). xfter washing with running' buffer; glycoproteins were eluted from the column with 0.5 M N-acetylglucosamine (NAG) in the running buffer.
Immunoblotting was carried out as described (Roerig et al., 1992 ) with 2 hr incubation with anti-MORl (552) or anti-TAG at a dilution of 1:2000 or 1:2500 at room temperature. Horseradish peroxidase-conjugated secondary antibodies, goat anti-rabbit IgG, or goat anti-mouse were used at a 1:5000 dilution. Immunoblots were developed with enhanced chemiluminescence kits (Amersham, Arlington Heights, IL).
Immunohistochemistry.
Transfected COS-7 and Neuro2a cells, grown on coverslips, were fixed with 4% paraformaldehyde and 0.2% picric acid in 0.1 M phosphate buffer (pH 6.9) for 1 hr. Cells were washed several times in phosphate buffer and then preincubated 1% normal goat serum, 1% bovine serum albumin, and 0.3% Triton X-100 to block nonspecific binding sites. The cells were incubated overnight at 4°C with a mixture of rabbit anti-MORl (1:5000) and a monoclonal antibody against the human influenza virus hemagglutinin epitope (12CA5, 1:800; Nimar et al., 1983) . The staining of cells was detected with a mixture of fluorescein isothiocyanate (1:50) and lissamine rhodamineconjugated antibodies (1:50).
Male Sprague-Dawley rats (body weight of 150-200 gm, pathogenfree; Harlan, WI) were anesthetized with chloral hydrate (350 mg/kg, i.p.) and fixed with 4% paraformaldehyde and 0.2% picric acid in 0.1 M phosphate buffer by vascular perfusion as previously described (Wessendorf and Elde, 1985) . The spinal cord and brain were dissected and transferred to 10% sucrose buffer solution for at least 4 hr before cutting. Slide-mounted cryostat sections (lo-14 km) and free-floating freezing-microtome sections (40-50 pm) were processed for indirect immunofluorescence histochemistry (Coons, 1958) . Cryostat sections were incubated with rabbit anti-MORl (1:5000) for 18-24 hr at 4°C; free-floating sections (1:20,000), for 48-96 hr. In some instances, double-and triple-labeling procedures were employed (Wessendorf and Elde, 1985; Staines et al., 1988; Wessendorf et al., 1990 ) using antibodies to enkephalin, DORl, tyrosine hydroxylase, dopamine B-hydroxylase, tau, MAP2, synaptophysin, GFAP, or RT97. After being rinsed, the sections were incubated with secondary antisera (45 min at room temperature for cryostat sections; overnight at 4°C for free-floating sections).
Control sections were incubated with anti-MORl pretreated with homologous and heterologous peptides. Cross-reactivity controls for both primary and secondary antisera were done according to Wessendorf et al. (1990) .
Specimens were examined with a Bio-Rad MRC-1000 Confocal Imaging System (Bio-Rad Microscience Division, Cambridge, MA). For a detailed description of multicolor confocal laser microscopy, see Brelje et al. (1993) . The images shown are the results of projecting several optical sections taken at different depths in the section. Images were printed on a Fuji Pictography 3000 color printer at a resolution of 200 pixels/inch.
Preparution
of rihoprohe for MORl.
An antisense riboprobe for MORl was synthesized by linearizing MORl cDNA subcloned in the pRC/CMV plasmid with the restriction enzyme Std. Linearized plasmid (0.5 kg) was added to the reaction mixture (final volume of 20 ~1) containing transcription buffer (40 mM Tris-HCl, pH 7.5; 6 mM MgCl,; 2 mM spermidine; 10 mM NaCl), 10 mM DTT, 15 U of RNasin, 0.5 mM each ATP, GTP, and CTP, 12.5 mM UTP, 50 pCi of ?S-UTPaS, and 1 U of Sp6 RNA polymerase. The mixture was incubated at 37°C for 60 min followed by the addition 1 U of RQl RNase-free DNase to remove the template. After incubating at 37°C for an additional 15 min. the mixture was extracted with phenol/chloroform (2:l) once, and nonincorporated radioactivity was separated with RNA spin columns (Boehringer-Mannheim).
In situ hybridization. The methods used for in situ hybridization are similar to those reported elsewhere (Simmons et al., 1989) . Tissue for hybridization was obtained from male rats sacrificed by decapitation. Cryostat sections of 14 pm thickness were mounted on SuperFrost-Plus slides (Fisher Scientific, Chicago, IL), fixed in freshly made 4% formaldehyde (10 min at room temperature) and permeabilized with proteinase K (20 mg/ml in 1 M Tris, pH 8.0; 0.5 M EDTA; 8 min at room temperature). A second fixation in 4% paraformaldehyde (5 min at room temperature) was followed by an acetylation procedure using 0.1 M triethanolamine and acetic anhydride (400:1, v/v; 10 min). Sections were then rinsed in distilled water, dehydrated through graded alcohol, and allowed to dry. Sections were incubated with the riboprobe of 2 X 10h cpm/slide in hybridization buffer containing formamide, 20X hybridization salts, 10% SDS, Denhardts, DTT, and dextran sulfate at 60°C overnight. Washing began with 4X SSC (in sodium thiosulfate) at 37"C, followed by RNase treatment (20 ml of 0.5 M Tris, pH 8.0; 2 ml of 0.5 M EDTA, pH 8.0; 100 ml of 5 M NaCl; 50 pg/ml RNase; H,O to 1000 ml) at 45"C, then subsequent washing in decreasing concentrations of SSC. Sections were rinsed, dehydrated, and apposed to Hyperfilm-P max film (Amersham).
Results
Characterization of MORI antisera Antisera generated to the carboxy-terminus of MORl were determined to be immunologically selective for MORl by the combined results of several approaches. Central to these analyses was the expression of an epitope-tagged construct of MORl (MORTAG) in various cell lines. Immediately 3' to the start codon of MORI, a sequence was inserted that codes for the 9 amino acid epitope of the human influenza virus hemagglutinin protein followed by a 4 amino acid thrombin cleavage site (YP-YDVPDYALVPR, hereafter referred to collectively as "TAG"). This sequence can be readily detected with a commercially available monoclonal antibody (12CA5) and thus serves to identify independently the tagged receptor. The generation of such chimeric receptors by incorporating an easily localized exogenous epitope has been used for the characterization of adrenergic receptors (von Zastrow and Kobilka, 1992; Keefer and Limbird, 1993) as well as for a substance P receptor (Vigna et al., 1994) .
Immunojluorescent localization of epitope-tagged opioid receptors
In COS-7 cells electroporated with MORl cDNA, MORl immunoreactivity (-ir) was prominent in the plasmalemma, but was also observed in subcellular compartments that resembled the endoplasmic reticulum, Golgi apparatus, and vesicle-like structures (not shown). A similar staining pattern was observed in cells transfected with MORTAG (Fig. 1A) . In both cases, a similar fraction (-5%) of the cells on a given coverslip expressed detectable MORl-ir. In preparations transfected with MORTAG, only cells that expressed MORl-ir also expressed TAG-ir, and the subcellular pattern of staining was identical (Fig. lA,A' ). Pretreatment of anti-MORl with the cognate peptide prevented staining of MORTAG-transfected cells although the same cells were still vividly stained by anti-TAG; Fig. l&B') . These data strongly suggest that anti-MORl recognizes MORl per se. Staining obtained with anti-MORl was determined to be selective with respect to other members of the opioid receptor family, since COS-7 cells transfected with epitope-tagged constructs encoding 6-or K-opioid receptors were not stained (Fig.  lC,C',D,D' ).
vented by the addition of DAMGO, a p-opioid-selective ligand (Fig. 2, lane 2) . Further purification of this '251-P-endorphinlabeled protein complex using an immunoaffinity column constructed with an MORl antiserum (551) demonstrated an identical pattern of labeling (Fig. 2, lanes 3, 4) . Thus, the fraction retained in the immunoaffinity column was labeled by 125I-pendorphin. Together, these data suggest that the MORl antisera recognize the '251-~-endorphin/p-opioid receptor complex.
Western analysis
Membrane proteins derived from the Neuro2a cell line (Fig. 3 , lanes l), MORl-Neuro2a (lanes 2, 4), MORTAG-Neuro2a (lanes 3, 5, 6), and rat brain (lanes 7) were partially purified using a wheat germ lectin column, separated by SDS-PAGE, blotted onto nitrocellulose, and probed with either the MORl antisera (552; Fig. 3A ) or anti-TAG (Fig. 3B) . Membrane proteins isolated from cells transfected with MORl and eluted from a wheat germ lectin column using NAG contained several closely migrating bands with relative molecular weights of 67-72 kDa that were stained by anti-MORl in the absence (lanes I and 3) and presence (lanes 2 and 4) of 100 nM DAMGO. Partiallv ourified membrane extracts (over a wheat germ lectin column) revealed a diffuse band at 63-67 kDa (lane I). Labeling was prevented by DAMGO (lane 2). The same diffuse band was seen after further purification using an immunoaffinity column constructed with anti-MORl (551; lane 3) but was absent in the presence of DAMGO (lane 4).
Immunoisolation of a '251-P-endorphin/receptor complex
Earlier cross-linking studies with '251-13-endorphin and rat brain membranes indicated that the p,-opioid receptor has mass of 65 kDa (Howard et al., 1985) . As shown in Figure 2 , membrane proteins from Neuro2a cells transfected with MORl that were cross-linked with lz51-P-endorphin and eluted from a wheat germ lectin column with NAG revealed a diffuse band with a molecular mass of 63-67 kDa (Fig. 2, Anti-MORl Anti-TAG Figure 3 . Immunolabeling of membrane proteins with anti-MORI and anti-TAG. Western analysis of partially purified extracts from Neuro2a cells stably expressing either MORI or MORTAG is shown using anti-MORl (552; A) and anti-TAG (monoclonal 12CA5; B). In both A and B, lanes 1-3 and 7 represent membrane preparations partially purified over a wheat germ lectin column; lanes 4 and 5 represent preparations partially purified by column chromatography first using wheat germ lectin and second using an immunoaffinity column constructed with anti-MORl (551); lanes 6 are identical to lanes 4 and 5 except that it was immunoaffinity purified using a column constructed with anti-TAG. No staining was seen in membrane preparations from nontransfected cells (A, B, lanes I). Membranes from MORl-Neuro2a cells contained proteins with a molecular weight of 67-72 kDa that were stained using anti-MORl (A, lanes 2 and 4) but not using anti-TAG (B, lanes 2 and 4). Similar bands from MORTAG-Neuro2a ceils were stained using both anti-MORl (A, lanes 3, 5, and 6) and anti-TAG (B, lanes 3 and 5). Lanes 6 were not informative due to leeching of anti-TAG from the affinity support (B, lane 6). Rat brain membrane preparations contained protein(s) with similar molecular weight that could be stained using anti-MORI (A, lane 7; digitally enhanced in lane 7') but not with anti-TAG (B, lane 7). The amount of protein loaded from Neuro2a extracts was equivalent to 0.5 mg of membrane proteins. Rat brain membrane was loaded at an equivalent of 6 mg of the membrane protein.
isolated from cells transfected with MORTAG and those that were eluted from an immunoaffinity support constructed with anti-TAG.
Anti-MORI stained proteins with molecular weight of 67-72 kDa in this eluate (Fig. 3A , lane 6) suggesting that anti-MORl and anti-TAG recognized the same protein(s). As expected, neither anti-MORI nor anti-TAG recognized proteins in nontransfected Neuro2a cells (Fig. 3A,B, lanes 1 blocked the staining at concentrations as low as 10-h M (not shown). Thus, the epitope for anti-MORl seems to be within the last 5-8 amino acids of the receptor.
Cellular distribution of MORI
A large number of MORl -ir cell bodies and their processes were stained in brain. To analyze the compartmentalization of MORl in neurons, double-immunolabeling experiments were performed using anti-MORl and specific markers for each compartment. Antibodies to tau and synaptophysin (~38) were used to mark axons, whereas antibodies to MAP2 were used to mark dendrites. In addition, antibodies to GFAP were used as a marker for glia. Throughout the brain and spinal cord, MORl-ir was primarily localized in the somatodendritic domain of neurons, although instances of MORl staining in axons were also found. No MORI staining associated with glia was observed.
Different cellular and subcellular patterns of MORl-ir were observed in neurons in the brain and spinal cord. In one group of neurons (including cortical neurons in laminae II and III and in the hippocampus), MORl-ir was seen as small puncta within the cytoplasm of perikarya and within processes (Fig. 4A,B) .
These puncta could possibly represent vesicles transporting the receptor to or from its target (in the text these puncta will also be referred to as vesicle-like structures). Labeling could also sometimes be seen in the plasmalemma of these neurons. In a second group of neurons (including cells in the superficial dorsal horn of the spinal cord) MORl-ir was seen mainly in the plasmalemma of perikarya but also extended into the primary dendrites (Fig. 40) . Labeling of plasmalemma was in some cases not continuous; instead labeling was concentrated in small clusters (Fig. 4E) . In a third group of neurons MORl-ir was observed within axons (including fasciculus retroflexus and the accessory medial optic tract; Fig. 4F) . In a few axons, MORlir could be found in vesicle-like structures within varicosities as w.ell as in intervaricose segments (Fig. 4G ).
Distribution of MORI in brain
MORl -ir was found in a number of regions throughout the brain and spinal cord. Two basic patterns of MORl-ir were discerned. Neuronal perikarya and/or dendrites with prominent MORl-ir were found in the cerebral cortex, striatum, nucleus accumbens, the septal nuclei, islands of Calleja, hippocampal regions, amygdaloid nuclei, several thalamic nuclei, habenular nuclei, interpeduncular nuclei, several raphe nuclei, the colliculi, parabrachial nuclei, locus coeruleus, nucleus ambiguus, nuclei of the sensory trigeminal complex, nucleus of the solitary tract, and the spinal cord dorsal horn. Instances of axons with prominent MORl -ir were less common and were found in the pre-and parasubiculum, fasciculus retroflexus, accessory optic tract, and in primary afferent neurons terminating in the superficial dorsal horn of the spinal cord and sensory trigeminal complex. In general, the distribution of perikarya and dendrites correlated well with the distribution of neurons expressing mRNA encoding for MOR 1, and was similar to the distribution of enkephalin. Details of the targeting of MOR I -ir for several brain regions that have been important models for investigation of opioid function are presented below.
Striaturn. Dense MORl-ir was seen in patches in the striatum and in the subcallosal streak (Fig. 5A,B) . There was also weak staining between the patches. Labeling was strongest in the patches located in the rostral-lateral portion of the striatum. A similar pattern of patches was revealed using in situ hybridization for MORI (Fig. 5D ). In addition, patches of dense MORlir were observed in the nucleus accumbens as well as in the islands of Calleja. At higher magnification (Fig. 5C ) fine, diffuse, punctate MORl-ir was seen within the patches. This punctate staining surrounded small round profiles and may represent clusters of MORl in the postsynaptic membrane of dendrites or clusters of receptors in the presynaptic membrane of nerve terminals. However, the former is likely, based upon double-staining experiments in which MORl-ir coincided more frequently with MAP2-ir, rather than tau-or synaptophysin-ir (data not shown). Although dendrites appeared to be labeled, neuronal perikarya containing MORl -ir were not obvious within the striaturn. Double staining using anti-MORl and anti-enkephalin showed a fine, punctate network of enkephalin-ir varicosities throughout the striatum including areas within the MORI-ir patches. At higher magnification (see Fig. 9A ) enkephalin-ir was found in puncta that were separate from but closely apposed to MORI -ir elements.
Hippocampal formation. At low magnification, dense MORlir was seen in the pre-and parasubiculum, angular bundle, dentate granule cell layer, and in the pyramidal cell layer of Ammon's horn (Fig. 6A) . In the superficial laminae of the entorhinal cortex a few cells with processes projecting toward deeper laminae were observed to contain MORl-ir.
In the pre-and parasubiculum, anti-MORl labeled a fine, but very dense network of axons. At higher magnification staining in the hippocampus was observed in both perikarya and dendrites. Perikarya of granme cells near the interface of the granule cell layer and the hilus of the dentate gyrus were decorated with MORl-ir.
The dendrites of these cell were also prominently labeled, but the labeling faded as they extended into the molecular layer (Fig.   6B,D) . The hilus contained a few MORl-ir neurons and also a fine network of thin, nonvaricose processes. MORl -ir coincided with the plasmalemma of perikarya and apical dendrites of cells within the pyramidal layer throughout the extent of Ammon's horn (regions CAl-CA3; Fig. 6A,C,E) . Staining within the apical dendrites was prominent as they coursed through the stratum radiatum and expanded into a more diffuse pattern in the stratum lacunosum-moleculare, where they arborized.
The basal dendrites of these cells also contained puncta of MORl -ir and some __ ___ ^ ^ with anti-MORl using immunofluorescence as visualized by confocal microscopy. Coronal secttons from layers II-111 ot trontal cortex showed MORl-ir in cell bodies and processes (A-C). Higher magnification of cortical neurons revealed MORl-ir was associated with vesicle-like structures in the perikarya as well as in primary processes (B) . No staining was seen after preabsorption with cognate peptide (C). Parasagittal section from the superficial dorsal horn of the spinal cord demonstrated MORl-ir within the plasmalemma of the perikarya as well as the dendrites (0, E). Note that MORl-ir was concentrated in clusters along the membrane (E). F, Coronal section from the midbrain demonstrated MORl-ir in the axons of fasciculus retroflexus (arrow) and accessory medial optic tract (arrowheads). G, High magnification of varicose fiber from the brainstem showed an accumulation of MORl-ir within vesicle-like structures in both varicosities and intervaricose segments. Scale bars: A, C, and D, 25 pm; B, E, and G, 10 pm; F, 1000 pm. in patches as well as in the subcallosal streak. Weak labeling was also present in the neuropil between the patches (B). A fine, punctate labeling rell as a more diffuse labeling was seen in the patches at higher magnification (C). Note clustering of MORl-ir around small-diameter (l-3 circular profiles, presumably dendrites, in the patches (C). Using in situ hybridization, patches of cells expressing MORI mRNA resembled aatches seen using anti-MORl. Arrows in A and B refer to areas shown at higher magnification in B and C, respectively. Scale bars: A, 1000 km; B, 500 km; C, 25 pm; D, 5000 pm. of these processes could be identified in their course toward the stratum oriens (Fig. 6C,E) . Sparsely dispersed cells in stratum oriens also showed MORl-ir. Enkephalin-ir fibers were seen throughout the hippocampal formation. However, particularly dense ENK immunoreactivity was seen in the pyramidal cell layer of CA2 and CA3, in the hilus of the dentate gyrus, and in the mossy fiber area. MORl-ir profiles were seen in close proximity to ENK-ir fibers in CA2 and CA3, but no unequivocal instances of a perfect match were found (not shown).
Locus coeruleus. Prominent MORl-ir was seen in the locus coeruleus (Fig. 7A) . This correlated well with MORl mRNA expression as determined by in situ hybridization (Fig. 7C) . As in the striatum, a combination of diffuse and punctate staining was seen at higher magnification (Fig. 7B) . MORI-ir was seen outlined the contours of some perikarya and small rounded profiles within the neuropil. MORl-ir was not apparent within the cytoplasm of neurons in locus coeruleus. Enkephalin-ir within locus coeruleus was sparse but mingled among MORl-ir perikarya and dendrites (see Fig. 9B ). Double-labeling experiments using anti-MORl and antibodies to dopamine P-hydroxylase or tyrosine hydroxylase were carried out on sections sampled from throughout the brain and spinal cord known to receive input from axons of locus coeruleus neurons. Few cases of coexistence were observed, suggesting that targeting of MORI in locus coeruleus neurons is restricted to the somatodendritic domain, and not axons.
Spinal cord dorsal horn. The superficial dorsal horn of the spinal cord contained a dense network of MORI-ir at all spinal levels (Fig. 8A) . This network consisted not only of varicosities (Fig. 8F) but also of the plasmalemma of neuronal perikarya and dendrites (Figs. 4D,E; SF; 9C). In parasagittal sections, perikarya exhibiting MORl-ir could be seen to extend their processes in a rostrocaudal orientation (compare Figs. 40, 9C with 8F) . The staining of MORl-ir varicosities in the superficial dorsal horn decreased after dorsal rhizotomy (Fig. 8B) whereas the staining for MORl-ir in perikarya in this region was not altered, supporting the idea that many of the axons with MORl-ir in the dorsal horn originate from dorsal root ganglion cells. This is Figure 6 . Localization of MORl-ir in the hippocampal formation: horizontal section stained with anti-MORl. A, Low-power confocal image illustrating the widespread distribution of MORl-ir in the hippocampal formation. Note the dense accumulation of MORl-ir in the pre-and parasubiculum, in the dentate granule cell layer, and in the pyramidal cell layer of Ammons horn. In the dentate gyms, MORl-ir was seen within the somatic and dendritic plasmalemma of granule cells (B, D). Note weak staining of cells and processes in the hilar region (B). A subset of pyramidal cells in the CA1 region of Ammons horn exhibited MORl-ir in puncta within the cytoplasm of perikarya and processes as well as in the plasmalemma of the soma and the basal and apical processes (C, E). Arrows labeled B-E refer to the areas shown at higher magnification in panels B-E, respectively. Orientation given in A applied to all plates. Scale bars: A, 1000 pm; B and C, 100 pm; D and E, 25 km.
further supported by evidence showing that a subset of neurons in dorsal root ganglia stained with anti-MORl (Fig. 8C) . In these cells a punctate staining pattern was seen within the cytoplasm and axoplasm, as well as in the somatic plasmalemma (Fig. 80) ; the punctate staining could possibly represent vesicles transporting the receptor. Neurons in dorsal root ganglia containing MORl-ir were small to medium in size and did not stain for RT97, a neurofilament protein seen in large myelinated primary afferents (Fig. 8E,E' ). This suggests that MORl is localized to neurons that give rise to unmyelinated primary afferents. In addition to double-labeling experiments with anti-MORl and enkephalin, double-labeling experiments were performed with an antiserum to another enkephalin-preferring opioid receptor, namely the &opioid receptor (DORl; Dado et al., 1993; Arvidsson et al., 1995) . In contrast to labeling for MORl, no evidence for labeling of postsynaptic structures could be seen for enkephalin or DORl. In the superficial dorsal horn, varicosities coexpressing MORl and DORl could be seen (Fig. 8FJ') . The same pattern of coexistence was observed in neurons in DRG. No such coexistence was seen in the dorsal horn after dorsal rhizotomy. The distribution of MORl and enkephalin in the dorsal horn overlapped in superficial dorsal horn but not in deeper laminae (Fig. 9C) . Occasionally, several enkephalin-immunopositive varicosities were seen in the vicinity of MORl-positive clusters in the plasmalemma (arrow in Fig. SC) .
Discussion
The pattern of receptors on the plasmalemma of neurons determines the nature of neurotransmission. Synaptic neurotransmission, as at the neuromuscular junction, requires targeting of receptors to the postsynaptic membrane immediately subjacent to the site of transmitter release. Little is known concerning the (A, B) , and autoradiograph after i n situ hybridization for MORI mRNA (C). Dense MORlir was seen in the somatic plasmalemma (UYYOW.S i n B) of locus coeruleus neurons as well as in the neuropil surrounding cross-sectioned profiles (A, B). B is a higher-magnification image from the same field as A. Neurons in locus coeruleus were also strongly la- trafficking of neuropeptide receptors. To date DORI has been shown to be targeted primarily to axons, where it most likely functions presynaptically (Dado et al., 1993; Arvidsson et al., 1995) , whereas a substance P receptor has been shown to be targeted to the plasma membrane of the somatodendritic domain, where it most likely functions postsynaptically (Liu et al., 1994; Nakaya et al., 1994) . Thus, it was of interest to determine if neurons were capable of targeting MORI to axons or somatodendritic domains, or both.
Speci&it~ of MORI untiseru
The antisera used in these studies were raised against a synthetic peptide corresponding to the last 15 amino acids of the C-terminus of MOR 1 (Chen et al., 1993; Fukuda et al., 1993; Thompson et al., 1993) . Both tissue sections and transfected cell lineq could be immunostained with these antisera and the staining was abolished when anti-MORI cera were preincubated with the peptide against which they were raised. Based on epitope mapping studies, all antisera appeared to have a similar epitope, which was determined to be within the last 5-8 amino acids. Further characterization demonstrated that the antisera detected proteins with an M, of 67-72 kDa on Western blots of membrane proteins from brain and transfected cells. It should be noted that the MORI cDNA clone predicts a protein with a mass of 45 kDa. However, the sequence has five potential sites for N-linked glycosylation, two consensus sites for palmitoylation and three poc\ible sites for phosphorylation (Thompson et al., 1993) . Thu\, the discrepancy in the predicted mass of MORI and the apparent mass of MORl-ir as determined by Western blots is likely a result of posttranslational modifications. Other points further support the specificity of the antisera. The antisera (1) immunoisolated a membrane protein capable of binding P-endorphin and having a molecular weight of 63-67 kDa, (2) stained COS-7 and Neuro2a cell lines transfected with MORl, (3) stained only those COS-7 and Neuro2a cells that were also stained for TAG (in preparations transfected with MORTAG), (4) were selective for the p-opioid receptor, since cell lines transfected with S-or K-opioid receptors were not stained by the antisera, and (5) stained brain and spinal cord in a pattern that mirrored that seen in autoradiographic studies of opioid binding as well as a pattern similar to that seen by in situ hybridization for MORl. Thus, several lines of evidence support the conclusion that the antisera used in the present study most likely recognize a bona fide FL-opioid receptor.
Our findings with these antisera differ substantially from those in a recent report (Hiller et al., 1994) in which antisera were raised against a peptide from a p-opioid binding protein isolated from bovine brain. Our findings also differ from an earlier report (Hassan et al., 1989 ) that used anti-idiotypic antibodies that recognize both p-and S-opioid receptors. In each of these studies it is possible that the proteins they have localized may be k-opioid receptors; however, they are clearly not MOR I.
Intrucellular
targeting of MORI und compurison to DORI Study of the cellular distribution of opioid receptors in neurons is important as a first step in determining the mechanisms by which they traffic. MORI is found predominantly in the somatodendritic domain. However, the somatodendritic distribution of MORI was different among different groups of cells: in the superficial dorsal horn of the spinal cord the receptor was visible only on the plasmalemma, whereas in the cerebral cortex, hippocampus, and dorsal root ganglia it was visible in the cytoplasm and occasionally on the plasmalemma.
The reason for these differences is unclear, but it might be that differences exist in receptor turnover, trafficking, or rates of internalization.
Also, the immunoreactivity in some neurons could be seen in patches on the somatic and dendritic plasmalemma.
It would be of interest to determine whether the receptor at these sites is concentrated where presynaptic terminals containing endogenous opioids make contact (see below). Figure 8 . Localization of MORI-ir in the spinal cord and dorsal root ganglion cells: immunofluorescent confocal images of the dorsal horn and dorsal root ganglion stained with anti-MORI (A-F), RT97 (E'), or anti-DORl (F'). Dense MORI-ir was seen in the superficial dorsal horn (A). B, Seven days after a unilateral dorsal rhizotomy, a reduction of the labeling was apparent on the ipsilateral side, especially in lamina I and outer lamina II (arrows), but labeling remained in inner lamina 11. C, A subset of small-to medium-sized dorsal root ganglion cells demonstrated MORlir. At higher magnification, MORI-ir was observed in vesicle-like structures, and these were sometimes found in axons (D). In addition, MORl-ir was observed in the somatic plasmalemma of some neurons. The majority of the MORI-positive cells in the dorsal root ganglion did not stain for RT97 (E, E'). MORl-ir was found in the plasmalemma of small cells and their processes (F, curved arrow) as well as in axonal varicosities (F). MORI-ir was present in a subset of DORI-positive axonal varicosities in the dorsal horn (arrows in F, F'). Scale bars: A and C, 250 km; B, 500 pm; D, 10 pm; E and E', 20 p,m; F and F', 50 km.
In earlier studies axonal transport of opioid receptors was presicular compartment rather than within the plasmalemma. The dieted, for instance, in the projections of dorsal root ganglion latter also appears to be the case for DORl (Arvidsson et al., cells to the superficial dorsal horn (LaMotte et al., 1976; Zajac 1995) , and it is possible that neurotransmitter receptors on preet al., 1989; Besse et al., 1990; Laduron and Castel, 1990) and synaptic terminals are transported and inserted by a regulated in the accessory medial optic tract (Giolli et al., 1990) . In the rather than a constitutive pathway. The mechanism by which present study, MORl staining was seen within varicose fibers in MORl and DORl are inserted into the plasmalemma of termithe dorsal horn. Some of these fibers stained with markers for nals might be controlled in a manner similar to that of neuroaxons, anti-tau and anti-synaptophysin, as well. stance P and NPY Y I receptors both appear to be incorporated exclusively into the somatodendritic domain (Liu et al., 1994; Nakaya et al., 1994; Zhang et al., 1994) . The mechanisms by which neurons control the intracellular trafficking of receptors to axons versus dendrites or both are still not known.
Distribution
oj MORI in the rat brain and spinal cord
The overall distribution of MORI is in agreement with earlier studies on p-opioid binding sites in the brain and spinal cord (Mansour et al., 1987; Tempel and Zukin, 1987; Mansour and Watson, 1993) . Previous autoradiographic studies could not unequivocally identify the cellular location of these binding sites. However, immunocytochemical studies using antisera that recognize the receptor provide a more exact localization.
Comparison of our immunocytochemical data with in situ hybridization experiments showed that the regional pattern of MOR 1 -ir correlates well with the distribution of mRNA coding for MORI, as seen in the present article as well as in previous studies (Thompson et al., 1993; Delfs et al., 1994; Mansour et al., 1994) . Pharmacological studies have proposed on the basis of different binding characteristics of ligands the presence of two p,-opioid receptor subtypes referred to as p,l and p.2 (Pasternak, 1993), but it is presently unclear which of these corresponds to MORl.
The highest densities of MORl in the brain were found in the cortex, caudate-putamen, habenula and interpeduncular nuclei (as well as in the fiber bundles connecting these two areas), hippocampus, hypothalamic nuclei, raphe medianus, inferior colliculus, parabrachial nuclei, locus coeruleus, ambiguus nucleus, sensory trigeminal complex, nucleus of the solitary tract, and spinal cord dorsal horn. This distribution suggests that this receptor protein may be important in mediating functions such as motor rigidity, autonomic reflexes, endocrine functions, behavioral and mood effects as well as analgesia.
In the hippocampal formation MOR I -ir was prominent in the granule cell layer in the dentate gyrus as well as in the pyramidal cell layer of Ammon's horn. In both cases the staining was prominent in the plasmalemma of neuronal perikarya and dendrites. Electrophysiological studies on hippocampal slices have shown that activation of p.-opioid receptor decreases GABA release from interneurons leading to an indirect excitation of pyramidal neurons (i.e., disinhibition; Cohen et al., 1992; Thompson, 1994) . Disinhibitory mechanisms have also been reported for granule cells in the dentate gyrus (Xie et al., 1992) . Thus, our findings argue that at least some of the MORl-positive neurons represent GABAergic inhibitory interneurons. It should also be noted that the distribution of neurons containing MORI-ir resembles the distribution GABAergic neurons as determined by immunostaining for glutamic acid decarboxylase (Mugnaini and Oertel, 1985; see also Buhl et al., 1994) .
Release of noradrenaline from rat brain slices is inhibited by activation of p-opioid receptors (for references, see Mulder and Schoffelmeer, 1993) . Also, b-opioid receptor agonists inhibit noradrenaline release from synaptosomes (Mulder et al., 1987) , suggesting that p-opioid receptors occur on noradrenergic terminals. In the present study MORI-ir was seen in the somatic plasmalemma of locus coeruleus neurons, suggesting that the MORl receptor may be responsible for the effects of opiates on these cells (Harris and Williams, 1991) . However, in either the brain or spinal cord, very few DPH-or TH-positive axonal terminals stained for MORI, suggesting that MORl is not predominantly transported to noradrenergic terminals. The discrepancy between our anatomical findings and the previous pharmacolog-ical studies may be due to, as recently demonstrated, the existence of alternate splicing of p-opioid receptor mRNA producing different isoforms of the receptor (Zimprich et al., 1994) . This isoform, termed MOR I b, varies in length and the composition of the carboxy-terminus from MOR I. Since our antisera are directed against the last S-8 amino acids at the carboxyterminus, it is unlikely that anti-MORI would recognize the MORI b isoform. Thus, a plausible explanation could be that locus coeruleus neurons target MORI to their somatodendritic domain whereas MORI b is targeted to their axons. A test of this hypothesis awaits the availability of antisera selective for MORlb.
In the superficial dorsal horn MOR I -ir was present on membranes of neurons as well as on axon terminals. Some of the MORI-labeled terminals probably derive from dorsal root ganglion cells since a dorsal rhizotomy decreased the staining of MORI in laminae I and outer II. Thus, MORI appears to be localized both pre-and postsynaptically in the dorsal horn and therefore to be poised to modulate both the release of transmitters from primary afferent neurons and the responses of dorsal horn neurons. This conclusion is in agreement with numerous studies using electrophysiological, pharmacological, and anatomical techniques (Fleetwood-Walker et al., 198X; Besse et al., 1990; Dong et al., I99 I ; Herrero and Headley, 199 I ; Thompson et al., 1993; Glaum et al., 1994; Grudt and Williams, 1994) .
The population of dorsal root ganglion neurons that stained for MORI was predominantly negative for RT97, a marker for large, myelinated primary afferents (Lawson and Waddell, 1991) . This finding suggests that MORI is mainly localized to small-diameter primary afferent neurons, some of which mediate nociception.
Interestingly, a subset of MOR I -positive axon terminals in the superficial dorsal horn stained also for DORI. A &p-receptor complex has been suggested from the diverse and complex pharmacology of the opioids (for references, see Rothman et al., 1993) . Inhibition of substance P release from cat hypothalamic slices has been found to involve both a p-and a &opioid receptor (Micevych et al., 1984) . It remains to be determined whether similar regulation occurs in the dorsal horn.
As described above, p-opioid receptors may inhibit both primary afferent terminals as well as local neurons in the dorsal horn to produce antinociception.
In addition, areas implicated in supraspinal analgesia also stained for MOR I, including nucleus raphe magnus in the rostra1 ventromedial medulla and caudal pons, locus coeruleus, and the periaqueductal gray. This suggests that the p-opioid receptor also may be involved in descending mechanisms of antinociception that are mediated by opioids (see Basbaum and Fields, 1984) .
